Ocera Therapeutics Reports Second Quarter 2015 Financial Results
August 03, 2015 16:13 ET
|
Ocera Therapeutics, Inc.
Continued Strong Enrollment in STOP-HE On Track for Initiation of Phase 1 Trial with Oral Formulation of OCR-002 in Third Quarter $20 Million Debt Facility Extends Cash Resources to Mid-2017 PALO...
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference
May 29, 2015 13:30 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera CEO to be Honored at the 17th Annual American Liver Foundation's Salute to Excellence Awards Gala in San Francisco
May 04, 2015 08:35 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics Announces Change in Executive Team
May 04, 2015 08:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), today announced that Rajiv Patni, M.D., chief development officer, has decided to step down from his position...
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results
April 30, 2015 08:05 ET
|
Ocera Therapeutics, Inc.
Strong Enrollment in STOP-HE Trial
Conference Call and Webcast at 10:00 a.m. ET
PALO ALTO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage...
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results
April 22, 2015 16:43 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
April 01, 2015 17:03 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., April 1, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
March 11, 2015 16:01 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
December 03, 2014 08:01 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Reports Third Quarter 2014 Financial Results
November 13, 2014 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...